By Derrick Gingery / Email the Author / May 16, 2013
Executive Summary
Compounding manufacturers would have to report adverse events and quality problems much like traditional drug and biologic makers as a Senate committee moves toward mark up of legislation.
to purchase to read click here
No comments:
Post a Comment